Gastrin I (human): Advancing Proton Pump Activation in Intestinal Organoid Models

Introduction

The study of gastrointestinal physiology and its regulatory mechanisms is critical to understanding both health and disease in the human digestive tract. Among the endogenous peptides central to this system, Gastrin I (human) is a potent gastric acid secretion regulator, acting through CCK2 receptor-mediated pathways. Historically, investigations have focused on in vivo models or transformed cell lines, yet recent advances in stem cell biology have revolutionized in vitro research platforms. In particular, human induced pluripotent stem cell (hiPSC)-derived intestinal organoids now provide robust, physiologically relevant models for probing intestinal function, drug transport, and receptor signaling (Saito et al., 2025).

This article provides an in-depth analysis of how the human Gastrin I peptide can be leveraged in these next-generation organoid systems to dissect proton pump activation, CCK2 receptor agonist dynamics, and receptor-mediated signal transduction, with a focus on applications in gastrointestinal disorder research and pharmacokinetic modeling.

Gastrin I (human): Molecular Properties and Mechanistic Overview

Gastrin I (human) is a 17-amino-acid peptide with a molecular weight of 2098.22 Da (CAS: 10047-33-3). Its primary physiological role is to stimulate gastric acid secretion by binding to CCK2 (cholecystokinin B) receptors on gastric parietal cells. This receptor engagement triggers intracellular signaling cascades, notably phospholipase C activation and intracellular calcium mobilization, ultimately leading to activation of the H⁺/K⁺-ATPase (proton pump) and increased acid release. In vitro, this peptide serves as a precise tool for interrogating gastric acid secretion pathways, CCK2 receptor signaling, and the downstream mechanisms of proton pump activation.

Gastrin I (human) is supplied as a white lyophilized solid, exhibiting high purity (≥98% by HPLC and mass spectrometry). Its solubility profile is optimized for experimental flexibility: insoluble in water and ethanol, but readily soluble in DMSO at concentrations ≥21 mg/mL. For research applications, particularly those requiring high-fidelity receptor-mediated signal transduction studies, storage desiccated at -20°C is recommended, and prepared solutions should be used promptly to maintain activity.

Human Gastrin I Peptide in Advanced Organoid-Based Gastric Acid Secretion Pathway Research

Traditional models for studying gastric acid secretion and CCK2 receptor agonist activity include animal models and immortalized cell lines. However, species-specific differences and the limited physiological relevance of such models have prompted the need for systems that better recapitulate human tissue architecture and function. The emergence of hiPSC-derived intestinal organoids—3D multicellular constructs mimicking the structural and functional properties of native intestine—addresses these limitations (Saito et al., 2025).

These organoids contain multiple differentiated cell types, including enterocytes, goblet cells, enteroendocrine cells, and Paneth cells, and express relevant receptors and transporters. When cultured as two-dimensional monolayers, hiPSC-derived organoid epithelial cells retain the capacity for receptor-mediated responses, including those driven by the human Gastrin I peptide. This enables detailed study of gastric acid secretion pathways, as well as the interplay between CCK2 receptor signaling and other regulatory axes in gastrointestinal physiology studies.

Notably, the use of human Gastrin I peptide in these organoid systems allows for:

• Quantitative assessment of CCK2 receptor agonist efficacy: By titrating Gastrin I (human) and measuring intracellular calcium flux or downstream acid secretion, researchers can generate precise pharmacodynamic profiles.
• Analysis of receptor-mediated signal transduction: The peptide’s robust activity enables dissection of signal transduction pathways, including PLC activation, IP₃ production, and cross-talk with other GPCR pathways.
• Modeling of gastrointestinal disorder mechanisms: By applying Gastrin I (human) to organoids derived from patient-specific hiPSCs, investigators can model disease states such as hypergastrinemia, Zollinger-Ellison syndrome, or gastric atrophy, and test therapeutic interventions.

Leveraging Gastrin I (human) in Pharmacokinetic and Drug Discovery Research

The recent reference study by Saito et al. (2025) highlights the importance of physiologically relevant in vitro systems for pharmacokinetic studies. hiPSC-derived intestinal organoids were shown to express mature enterocytes with functional CYP enzymes and transporter activities. This advancement enables more predictive modeling of drug absorption, metabolism, and excretion compared to traditional Caco-2 or animal models, which often fail to recapitulate human-specific features.

In this context, Gastrin I (human) can be used to modulate and study the influence of gastric acid secretion on drug dissolution, stability, and absorption in organoid-based systems. For example, researchers can:

• Investigate the effect of CCK2 receptor signaling on the pH-dependent solubility of orally administered drugs.
• Assess how altered acid secretion, as mimicked by Gastrin I (human) stimulation, impacts the pharmacokinetics of acid-labile compounds.
• Utilize organoids with engineered genetic backgrounds to study the interaction between proton pump activation and drug transporter function.

Technical Considerations for Experimental Design

For optimal use in gastrointestinal physiology studies, several technical parameters should be considered when working with Gastrin I (human):

• Peptide Handling: Due to its insolubility in water and ethanol, dissolve Gastrin I (human) in DMSO (≥21 mg/mL) and dilute into culture medium immediately prior to use. Avoid prolonged storage of solutions to preserve activity.
• Concentration Selection: Pilot experiments may be required to determine the optimal dose for CCK2 receptor activation in different organoid lines or monolayer formats. Literature suggests nanomolar to low micromolar concentrations are physiologically relevant.
• Readout Assays: Combine peptide application with downstream readouts such as acid secretion assays (e.g., pH-sensitive dyes), calcium imaging, or transcriptomic analysis of CCK2 receptor target genes.

These practices ensure reproducibility and rigor in studies focusing on the gastric acid secretion pathway and receptor-mediated signal transduction.

Emerging Applications: Disease Modeling and Therapeutic Screening

The integration of Gastrin I (human) into advanced organoid models expands the frontier of gastrointestinal disorder research. For example, patient-specific hiPSC lines can be differentiated into intestinal organoids to model genetic or acquired defects in CCK2 receptor signaling. By applying the peptide in these systems, researchers can:

• Elucidate the contribution of aberrant Gastrin I-CCK2 signaling to disease phenotypes, such as excessive acid secretion or impaired mucosal defense.
• Screen small-molecule inhibitors or monoclonal antibodies targeting the Gastrin I pathway for therapeutic efficacy and toxicity.
• Study compensatory signaling mechanisms that arise in response to chronic peptide stimulation or receptor blockade.

These applications have significant translational potential, enabling bench-to-bedside insights into the pathogenesis and treatment of conditions like peptic ulcer disease, gastrinomas, and atrophic gastritis.

Methodological Integration with Other Regulatory Peptides

While the primary focus is on CCK2 receptor agonism, Gastrin I (human) can be used in combination with other regulatory peptides or growth factors to model complex physiological scenarios. For example, co-application with somatostatin analogs or proton pump inhibitors allows for the dissection of feedback loops controlling acid secretion. Furthermore, the modularity of organoid systems supports multiplexed pharmacological studies, enhancing their value for preclinical drug discovery pipelines.

Conclusion

The deployment of Gastrin I (human) as an experimental probe in hiPSC-derived intestinal organoids marks a significant advance in the study of gastric acid secretion, CCK2 receptor signaling, and gastrointestinal physiology. By enabling detailed mechanistic studies of proton pump activation and receptor-mediated signal transduction, this approach overcomes the limitations of traditional models and opens new avenues for gastrointestinal disorder research and pharmacokinetic evaluation.

Compared with previous articles such as "Gastrin I (human) in Intestinal Organoid Research: Advancing GI Modeling", which primarily surveyed general applications of Gastrin I in organoid systems, this article provides a focused, mechanistic exploration of proton pump activation and the integration of Gastrin I (human) into advanced pharmacokinetic and disease modeling workflows. By emphasizing experimental design, technical considerations, and translational potential, it extends prior discussions and offers practical guidance for scientists seeking to harness the full power of this peptide in next-generation GI research platforms.